Extended Data Fig. 4: Development of a CD8-restricted Gαs-DREADD transgenic mouse model.
From: The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure
a, Genotyping confirmation for CD8-GsD mice. Primers detecting the Gαs-DREADD, ROSA26, and E8i-Cre were used to confirm recombination by the Cre-recombinase. Information about primers and genotyping is listed in Supplementary Table 4. b, Effect of DCZ on circulating CD8, CD4, NK cells, and CD11b myeloid cells in the peripheral blood of CD8-GsD mice treated with tamoxifen and 5 doses of DCZ (n = 5 mice for -DCZ; n = 6 mice for +DCZ). c, Effect of DCZ on non-tamoxifen-treated CD8-GsD mice. Quantification of IFNγ and TNF and PD-1 and Tim-3 in non-tamoxifen-treated CD8 T cells treated with or without DCZ. The average frequency and s.e.m. are shown (n = 3 biologically independent samples). Statistical significance was determined by two-tailed unpaired Student’s t-test.
